HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,712 | +10.3% | 44,820 | +4.2% | 0.01% | 0.0% |
| Q2 2023 | $1,552 | +38.3% | 43,030 | +46.5% | 0.01% | +25.0% |
| Q1 2023 | $1,122 | -61.2% | 29,375 | -42.2% | 0.00% | -63.6% |
| Q4 2022 | $2,890 | -99.8% | 50,789 | +19.1% | 0.01% | +57.1% |
| Q3 2022 | $1,687,000 | +1.3% | 42,658 | +12.7% | 0.01% | 0.0% |
| Q2 2022 | $1,665,000 | +38.2% | 37,840 | +25.2% | 0.01% | +40.0% |
| Q1 2022 | $1,205,000 | +14.0% | 30,219 | +14.9% | 0.01% | +25.0% |
| Q4 2021 | $1,057,000 | -13.1% | 26,291 | -12.1% | 0.00% | -20.0% |
| Q3 2021 | $1,217,000 | -20.5% | 29,920 | -11.2% | 0.01% | -28.6% |
| Q2 2021 | $1,530,000 | +15.8% | 33,693 | +6.3% | 0.01% | 0.0% |
| Q1 2021 | $1,321,000 | +32.2% | 31,704 | +35.5% | 0.01% | +16.7% |
| Q4 2020 | $999,000 | -27.3% | 23,392 | -55.3% | 0.01% | -33.3% |
| Q3 2020 | $1,375,000 | -1.7% | 52,317 | +0.2% | 0.01% | 0.0% |
| Q2 2020 | $1,399,000 | – | 52,187 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |